Violation Tracker Individual Record
Pharmaceutical manufacturers Serono Laboratories Inc., EMD Serono Inc., Merck Serono S.A, and Ares Trading S.A. agreed to pay $44.3 million to resolve False Claims Act allegations in connection with the marketing of the drug Rebif. The settlement resolved allegations that Serono paid health care providers from the launch of Rebif in January 2002 through December 2009 to induce them to promote or prescribe Rebif, a recombinant interferon injectable that is used to treat relapsing forms of multiple sclerosis. Serono was alleged to have made payments to providers for hundreds of speaker training meetings and programs, as well as payments for attending consultant, marketing and advisory board meetings, all at upscale resorts and other locations. Serono's actions allegedly resulted in the submission of false claims to federal health care programs including Medicare and Medicaid for the payment of Rebif, i.e., claims that were tainted by kickbacks.